logo-loader

Orgenesis leading the charge at an exciting time for cell therapy

Last updated: 16:03 20 Oct 2022 EDT, First published: 06:00 16 Nov 2021 EST

Snapshot

  • Orgenesis sees 2Q revenue of $7.2M; eyes future sales from POCare platform
  • Orgenesis Inc outlines ways in which the group is aiming to combat the coronavirus
Orgensis CEO Vered Caplan

About the company

Orgenesis Inc is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies.

How it is doing

16 Aug 2022

Orgenesis (NASDAQ:ORGS) Inc announced second-quarter 2022 revenue of $7.2 million and provided a business update for the period ending June 30, 2022.

The global biotech company also said it secured a $10 million loan from investment firm Metalmark Capital Partners for Orgenesis (NASDAQ:ORGS)’ point of care (POCare) services business for treating patients.

“We are progressing with our transition to the second phase of the planned rollout of our POCare platform,” Orgenesis CEO Vered Caplan said in a statement.

“This includes revenue generation from the validation, process development, and supply of advanced therapies that utilize our POCare platform and Orgenesis Mobile Processing Units and Labs (OMPULs),” Caplan added.  

24 May 2022

Orgenesis (NASDAQ:ORGS) Inc, the global biotech company working to unlock the full potential of cell and gene therapies, has said it is entering the second phase of its POCare Platform rollout, and expects to benefit from recurring revenue streams from long-term contracts for the next two to three years.

This follows the building of a robust network of POCare centers across Europe, Asia and the Middle East and the implementation of its POCare supply strategy in the US, the company said.

03 May 2022

Orgenesis (NASDAQ:ORGS) Inc said that a consortium led by its subsidiary, MIDA Biotech, has won a 4-million-euro grant under the European Innovation Council Pathfinder Challenge Program which supports cutting-edge science and technology in order to create new market opportunities.

The consortium members include MIDA Biotech B.V., DeepMed IO, and Leiden University, with MIDA acting as the lead. The grant is for technologies enabling the production of autologous induced pluripotent stem cells (iPSCs) using microfluidic technologies and artificial intelligence (AI), the company said.

What management says

16 Sep 2020

Orgenesis Inc (NASDAQ:ORGS) CEO Vered Caplan updates Proactive on ways in which the group is aiming to combat the coronavirus. Caplan spoke to Proactive about its BioShield Program, which is designed to use neutralizing human antibodies as a possible rapid defense and to potentially mitigate the spread of viruses such as the coronavirus that causes the COVID-19 disease.

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

1 hour, 59 minutes ago